Brand-Name Semaglutide Shortage
Explosive demand outstrips FDA-approved manufacturing supply lines.
- 2022–24: FDA shortage status (multi-year listing)
- 2: Approved brand forms (Ozempic, Wegovy)
- ~7,500: Compounding pharmacies (US) (503A/503B sites)
- +400%: Search demand growth (peak shortage period)
Demand outpaces supply
GLP-1 demand surges past factory output capacity.
Shortage list mechanics
FDA shortage listing legally opens a compounding window.
Patients seek alternatives
Cost and access gaps push patients toward compounders.
Compounding Pharmacies Produce Alternatives
Base or salt-form semaglutide substitutes fill the market gap.
- Na / Acetate: Common salt forms (unapproved variants)
- Variable: Bulk API sourcing (domestic & overseas)
- None: FDA-approved status (compounded versions)
- ~80: 503B outsourcing facilities (FDA-registered subset)
Base vs salt-form
Salt forms differ chemically from the approved active molecule.
503A vs 503B rules
Oversight and testing rigor vary sharply between facility types.
No standardized formula
Each compounder sets its own recipe and process.
Quality Variability Across Batches
Dosing accuracy, sterility, and stability diverge between compounders.
- Rising: Dosing error reports (FDA adverse event data)
- Non-uniform: Sterility assurance (facility dependent)
- Limited: Stability data (no standardized studies)
- Wide: Vial concentration spread (lab testing findings)
Dosing inconsistency
Measured potency can deviate meaningfully from the label.
Sterility gaps
Non-sterile compounding raises injection contamination risk.
Stability unknowns
Shelf-life and storage data are often unverified.
Adverse Events Climb
Dosing errors, injection reactions, and impurities generate reports.
- Thousands: Poison center calls (multi-year total)
- Hundreds: Hospitalization reports (dosing-error linked)
- Elevated: Injection site reactions (vs brand product)
- Documented: Impurity findings (FDA lab testing)
Overdose incidents
Concentration errors have driven serious overdose events.
Local reactions
Injection-site irritation trends higher with compounded product.
Unknown impurities
Some tested vials contained unlisted related substances.
Brand-Name vs Compounded Risk Profile
Regulated consistency contrasts with compounded quality variability.
- ~97: Brand consistency score (out of 100)
- ~35: Compounded consistency (low QC) (out of 100)
- Brand only: FDA approval (compounded unapproved)
- Substantial: Risk gap (across all metrics)
Regulated pipeline
Brand product follows standardized, audited manufacturing.
Variable pipeline
Compounded quality tracks each pharmacy's own controls.
Informed choice
Risk differences matter most when supply gaps persist.
Brand-name vs compounded — risk summary